$ZYNE News Article - Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
https://marketwirenews.com/news-releases/zyne...49741.html